COMMUNIQUÉS West-GlobeNewswire

Tvardi Therapeutics to Participate in Upcoming Investor Events
21/05/2026
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting [...]
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
21/05/2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy [...]
FLYTE ACTIVATES HIGH-FREQUENCY MEMORIAL DAY WEEKEND FLIGHT NETWORK TO CAPTURE SURGING NORTHEAST DEMAND
21/05/2026
Company Deploys Scalable Short-Haul Model into Peak Travel Window as Millions Exit NYC Metro Flagship Routes to Nantucket, Hamptons, and Martha’s Vineyard Positioned for Immediate Revenue Acceleration and High [...]
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory [...]
NSK Dental Achieves Back-to-Back Top Ratings in Dental Product Shopper Peer Evaluations
21/05/2026
Ti-Max Z990L Earns 4.9 in 2024 and Ti-Max Z99L Earns a Perfect 5.0 in 2025 — Both the Highest-Ever Ratings in Their Respective Categories Hoffman Estates, IL, May 21, 2026 (GLOBE NEWSWIRE) -- NSK Dental (NSK/Nakanishi [...]
Realize Medical Appoints Entrepreneur and Investor Tom Kaneb to Board of Directors
21/05/2026
OTTAWA, Ontario, May 21, 2026 (GLOBE NEWSWIRE) -- Realize Medical , a global leader in immersive medical imaging and virtual reality solutions for surgical planning and medical collaboration, today announced the [...]
Nanobiotix annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
NewGenIVF Announces Strategic Investment Agreement with Tech Veteran Andy Cheung-Led K25.ai, an AI-Powered Live-Streaming Prediction Market, at US$100 Million Valuation
21/05/2026
Initial US$2 million strategic investment values K25.ai at US$100 million pre-money, with option to invest up to US$10 million if exercised in full; exclusive APAC agency partnership provides NewGenIVF with exposure to [...]
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
21/05/2026
PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
HNL Lab Medicine Receives 2026 Boomi Innovation Award for Advancing Integration and Automation in Healthcare
21/05/2026
ALLENTOWN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been named a recipient of the 2026 Boomi Innovation Award, a national recognition honoring organizations that are using data, integration, and [...]
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
21/05/2026
U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury [...]
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
21/05/2026
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate [...]
KOMO Biosciences Appoints Biologics Manufacturing Leader Darryl Sampey, PhD, to its Scientific Advisory Board
21/05/2026
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- KOMO Biosciences today announced the appointment of Darryl Sampey, PhD, to its Scientific Advisory Board. Dr. Sampey brings more than two decades of experience in [...]
SlimTide Examined: 2026 Consumer-Focused Analysis of Ingredients, Claims, and Label Transparency
21/05/2026
Gut Microbiome Support Formula with Chicory Inulin, Resistant Starch, and Akkermansia Muciniphila Explained for Consumer Research Miami, FL, May 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by [...]
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
21/05/2026
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering [...]
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
21/05/2026
Cardiovascular and Respiratory medicines to be supplied in Malaysia and the Philippines Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, [...]
JavaTide Examined: 2026 Analysis of Ingredients Profile, Dosage Accuracy, and Metabolic Support Claims
21/05/2026
Comprehensive Evaluation Examines JavaTide Formula, Manufacturing Standards, and Consumer Verification Data for Gut Health Supplement Market Austin, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Biodesix to Participate in Upcoming Investor Conferences
21/05/2026
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming [...]
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
21/05/2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date [...]

Pages